BioLineRx Begins Phase 1/2a Study of GLIX1 to Combat Glioblastoma BioLineRx has initiated a Phase 1/2a clinical trial for GLIX1, a promising new treatment for glioblastoma, targeting DNA damage response in cancer cells.

BioLineRx Begins Phase 1/2a Study of GLIX1 to Combat Glioblastoma #Israel #Tel_Aviv #BioLineRx #Glioblastoma #GLIX1

BioLineRx Reports 2025 Financial Performance and Strategic Developments for Future Clinical Trials BioLineRx is set to initiate a Phase 1/2a trial for GLIX1 in glioblastoma, highlighting significant financial results and ongoing research in cancer therapy.

BioLineRx Reports 2025 Financial Performance and Strategic Developments for Future Clinical Trials #Israel #Tel_Aviv #oncology #BioLineRx #GLIX1

BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping BioLineRx Ltd. announces its Q3 2025 financial results, alongside an update on corporate initiatives, including joint venture developments.

BioLineRx's Q3 2025 Financial Disclosure and Corporate Strategy Revamping #Israel #Tel_Aviv #BioLineRx #motixafortide #GLIX1

BioLineRx and Hemispherian Form Joint Venture to Advance GLIX1 for Glioblastoma Treatment BioLineRx Ltd. and Hemispherian AS have established a joint venture to develop GLIX1, a novel oral treatment for glioblastoma and other cancers, pending FDA approval.

BioLineRx and Hemispherian Form Joint Venture to Advance GLIX1 for Glioblastoma Treatment #Israel #Tel_Aviv #BioLineRx #GLIX1 #Hemispherian

Hemispherian's GLIX1 Receives FDA Clearance for Glioblastoma Treatment in Historic Move Hemispherian AS has received FDA IND clearance for GLIX1, the first drug targeting DNA repair vulnerabilities in glioblastoma and solid tumors.

Hemispherian's GLIX1 Receives FDA Clearance for Glioblastoma Treatment in Historic Move #Glioblastoma #Norway #Oslo #GLIX1 #Hemispherian

Hemispherian's GLIX1 Awarded FDA Orphan Drug Status for Malignant Glioma Treatment Hemispherian AS is pleased to announce that the FDA has conferred Orphan Drug Designation to GLIX1, a promising treatment for malignant glioma, enhancing its potential in oncology.

Hemispherian's GLIX1 Awarded FDA Orphan Drug Status for Malignant Glioma Treatment #Norway #Oslo #GLIX1 #Hemispherian #FDA_Orphan_Drug

Hemispherian's GLIX1 Receives Positive Opinion for Orphan Drug Designation in EU for Glioma Treatment Hemispherian AS announces a significant step with the EMA's positive opinion for GLIX1, a therapy for glioma, marking a vital milestone in cancer treatment advancement.

Hemispherian's GLIX1 Receives Positive Opinion for Orphan Drug Designation in EU for Glioma Treatment #Norway #Oslo #Glioma #GLIX1 #Hemispherian